

# The Unfolded Protein Response Modulates Disease Severity in Pelizaeus-Merzbacher Disease

Cherie M. Southwood,<sup>1</sup> James Garbern,<sup>1,3</sup>  
Wei Jiang,<sup>1</sup> and Alexander Gow<sup>1,2,3,4</sup>

<sup>1</sup>Center for Molecular Medicine and Genetics

<sup>2</sup>Department of Pediatrics

<sup>3</sup>Department of Neurology

Wayne State University School of Medicine  
Detroit, Michigan 48201

## Summary

The unfolded protein response (UPR) is a eukaryotic signaling pathway linking protein flux through the endoplasmic reticulum to transcription and translational repression. Herein, we demonstrate UPR activation in the leukodystrophy Pelizaeus-Merzbacher disease (PMD) as well as in three mouse models of this disease and transfected fibroblasts expressing mutant protein. The CHOP protein, widely known as a proapoptotic transcription factor, modulates pathogenesis in the mouse models of PMD; however, this protein exhibits antiapoptotic activity. Together, these data show that the UPR has the potential to modulate disease severity in many cells expressing mutant secretory pathway proteins. Thus, PMD represents the first member of a novel class of disparate degenerative diseases for which UPR activation and signaling is the common pathogenic mechanism.

## Introduction

Of the myriad physiological processes ongoing in all living organisms, few are more important to survival at the levels of the cell and the organism than adaptation to stress. Primordial lifeforms contended with ever changing environmental conditions by rapid changes at the transcriptional and posttranscriptional levels, and since that time, virtually all species have retained and expanded such rudimentary signaling cascades to sustain life under adverse conditions. The unfolded protein response (UPR) is a stress-induced signaling cascade in eukaryotes, and recent appreciation of its importance as a central regulatory circuit in the secretory pathway has prompted broad interest in consequences to cells should the UPR be disrupted or overwhelmed (Travers et al., 2000). Indeed, correlative evidence implicates the UPR in a number of genetic diseases (Aridor and Balch, 1999). For example, mutations in the *PRESENILIN* gene from familial Alzheimer patients cause abnormal IRE1 processing (Katayama et al., 1999; Niwa et al., 1999). In this instance, the molecular defect alone does not compromise UPR induction (Sato et al., 2000) but, conceivably, may sensitize neurons to other insults.

We have investigated molecular pathogenesis of the leukodystrophy Pelizaeus-Merzbacher disease (PMD), a neurodegenerative disease causing diffuse hypomyelination of the central nervous system (CNS). PMD is

an X-linked recessive pediatric disorder characterized by three common genetic forms of disease: coding region or splice site mutations, duplications of the wild-type *PLP1* gene, and null alleles. These mutations yield a broad spectrum of disease phenotypes from severe, congenital disease to mild forms characterized by pure spastic paraparesis (reviewed in Garbern et al., 1999; Southwood and Gow, 2001). Mutant alleles that model all three of these genetic forms of PMD are available in mice, including (1) *myelin synthesis-deficient* (*msd*), an A242V missense mutation causing severe disease, also identified in patients (Gencic and Hudson, 1990; Yamamoto et al., 1998) and *rumpshaker* (*rsh*), an I186T missense mutation causing mild disease, also found in patients (Kobayashi et al., 1994; Schneider et al., 1992); (2) *4e-Plp*, comprising supernumerary copies of a 40 kb wild-type *Plp1* transgene causing overexpression (Kagawa et al., 1994); and (3) *Plp1* null (Klugmann et al., 1997; Rosenbluth et al., 1996; Stecca et al., 2000). Disease in *msd* mice is apparent by 12 days postnatal (P12) as moderate tremors, which rapidly progress through severe tremors to seizures causing death by 3–4 weeks. On the other hand, *rsh* mice develop symptoms by P14–16, exhibit moderate tremors and ataxia, but rarely exhibit seizures and have a normal life span (Fanarraga et al., 1992; Griffiths et al., 1990). Disease severity caused by *PLP1* gene duplication is proportional to the degree of overexpression (Ikenaka and Kagawa, 1995), and null alleles cause mild disease.

Molecular mechanisms underlying the phenotypes of most *PLP1* mutations are virtually unknown. Morphological analyses of oligodendrocytes from animal models indicate that distinct cellular defects underlie pathogenesis of different genetic forms of PMD. For example, several missense mutations perturb endoplasmic reticulum ultrastructure (Duncan, 1990); *PLP1* overexpression causes swelling of the Golgi apparatus and aberrant cholesterol trafficking (Kagawa et al., 1994; Readhead et al., 1994; Simons et al., 2002); and null alleles cause axonal abnormalities with late Wallerian degeneration and oligodendrocyte loss (Griffiths et al., 1998; Stecca et al., 2000).

Herein, we investigate involvement of the UPR in pathogenesis arising from *PLP1* coding region mutations and demonstrate that several mutations activate this signaling cascade. CHOP is induced in and localized to the nuclei of transfected fibroblasts expressing mutant *PLP1*, cultured oligodendrocytes from *msd* mice, and oligodendrocytes from *rsh* and *msd* mice expressing mutant *Plp1* gene products in vivo. Moreover, we show by Northern blotting and immunocytochemistry that CHOP is induced in oligodendrocytes from a PMD patient harboring a splice site mutation that excludes exon 6 from *PLP1* gene products. Finally, we directly demonstrate that CHOP modulates disease severity in *rsh* mice and normally serves to protect oligodendrocytes from apoptosis. Together, these data provide compelling evidence that the UPR is relevant to pathogenesis in PMD, thereby attesting to the importance of this regulatory pathway in disease. More broadly,

<sup>4</sup>Correspondence: agow@genetics.wayne.edu

suppositions by others that mutant secretory pathway proteins cause disease in different cell types through activation of the UPR portends PMD as the first example of a novel class of disparate degenerative diseases that nevertheless arise from a common molecular mechanism.


## Results

The UPR has been examined in yeast and cultured mammalian cells following induction by noxious stimuli such as tunicamycin to inhibit glycoprotein synthesis, thapsigargin to mobilize internal  $\text{Ca}^{2+}$  stores and expression of mutant secretory pathway proteins that accumulate in the endoplasmic reticulum (ER). Currently, the UPR is known to be activated through posttranslational processing of three ER-resident proteins, the Ire1 and PERK receptor kinases and the membrane-tethered transcription factor ATF6. These initiating proteins regulate translation of mRNAs encoding the XBP-1 and ATF-4 transcription factors and the expression of effector genes, including molecular chaperones and additional transcription factors such as CHOP and ATF3 (reviewed in Ma and Hendershot, 2001; Zinszner et al., 1998). Given the complexity of the UPR and our incomplete knowledge of this signaling cascade, we contend that the most reliable reporters of a UPR "in progress" are the effector molecules. In this regard, CHOP is downstream of PERK, BiP is downstream of Ire1, while Erp59 and Erp72 are downstream of ATF6 (Harding et al., 2000; Ma et al., 2002; Okada et al., 2002).

### CHOP Is Expressed in Fibroblasts Transfected with Mutant *PLP1* Constructs

To determine if the UPR is induced in vitro by mutant forms of *PLP1* gene products, we transiently transfected COS-7 cells with plasmids encoding either wild-type *PLP1* or the missense mutant from *msd* mice (*PLP1<sup>msd</sup>*). At 24 hr, essentially all transfected cells expressing *PLP1<sup>msd</sup>* localize this protein in the ER (green staining in Figure 1Aa) as demonstrated previously (Gow et al., 1994a, 1994b). Most transfected cells also express CHOP (white/pink staining, arrowheads), which colocalizes with the nuclear stain DAPI (blue). In contrast, the overwhelming majority of nontransfected cells are CHOP negative, indicating that the experimental procedure alone does not induce this gene. Transfected cells that express wild-type *PLP1* transport this protein to all major compartments of the secretory and endocytic pathways (arrows), as shown previously (Gow et al., 1994a), but the vast majority of these cells are CHOP negative (Figure 1Ab).

Cell counts demonstrate that CHOP expression strongly correlates with the expression of mutant but not wild-type *PLP1*. Transfected cells ( $n = 200$ ) labeled with antibodies against *PLP1* and CHOP in duplicate plates from two independent experiments are characterized in Figure 1B using several criteria. First, transfected cells are represented as a proportion of total cells (white bars *i* and *iv*). This transfection efficiency is similar for *PLP1* and *PLP1<sup>msd</sup>* expressing cells ( $\sim 20\%$ ) and rules out significant contributions from differences in plasmid toxicity. Second, dark bars (*ii* and *v*) represent double-



**Figure 1.** The UPR is induced in cells expressing mutant *PLP1*. (A) Transfected COS-7 cells expressing mutant (Aa) but not wild-type (Ab) *PLP1* (green) localize CHOP (red) in the nucleus (blue). Arrowheads show CHOP<sup>+</sup> cells (pink/white nuclei). Scale bar, 20  $\mu\text{m}$ . (B) Morphometry of transfected COS-7 cells showing transfection efficiency (bars *i* and *iv*) and *PLP1<sup>+</sup>/CHOP<sup>+</sup>* cells expressed as a proportion of transfected (*ii* and *v*) or stressed (*iii* and *vi*) cells. (C) Northern blots show induction of UPR effector genes in 293T cells untreated (NT), treated with tunicamycin (Tunic), or transfected with wild-type or mutant *PLP1*. (D) Oligodendrocyte progenitors from wild-type mice (Da) elaborate cell processes, differentiate, and incorporate *Plp1* gene products into the plasma membrane (green). Progenitors from *msd* mice also extend processes, which are subsequently resorbed (arrows) after the cells differentiate and express the *Plp1* gene (Db). These cells localize CHOP (red) in the nucleus which appears as yellow/orange (arrowheads). Scale bar, 10  $\mu\text{m}$ .

labeled cells (*PLP1<sup>+</sup>/CHOP<sup>+</sup>*) as a proportion of transfected cells (*PLP1<sup>+</sup>*). Only 10% of cells expressing wild-type *PLP1* also express CHOP; however, 70% of cells expressing *PLP1<sup>msd</sup>* also express CHOP. Third, bars *iii* and *vi* show that most CHOP-positive cells express *PLP1* ( $\sim 85\%$ ), which indicates that transfection conditions alone do not induce CHOP expression. Consistent with this finding, few cells from cultures transfected without plasmid DNA or with an empty expression plas-

mid express CHOP (1.5%–4%). On the other hand, 93% of untransfected cells treated with 2  $\mu$ g/ml of tunicamycin for 4 hr are strongly labeled by anti-CHOP antibodies. Together, these data clearly indicate that the UPR is activated by inhibiting N-glycosylation and by expressing mutant forms of PLP1 that accumulate in the ER.

From Northern blots, we find that several UPR effector genes are induced in tunicamycin-treated and PLP1<sup>msd</sup>-expressing 293T cells (Figure 1C). Steady-state levels of mRNAs encoding the transcription factors *Chop* and *Atf3* as well as the molecular chaperones *BiP*, *Erp72*, and possibly *Erp59* are induced in these cells compared to controls. Together, these data reflect activation of Ire1, PERK, and ATF6. On the other hand, the level of activation of downstream target genes differs between tunicamycin-treated and PLP1<sup>msd</sup>-expressing cells. For example, inhibiting glycoprotein synthesis induces *CHOP* ~5-fold more effectively than expressing PLP1<sup>msd</sup> on a per cell basis (we routinely obtain 50% transfection efficiency in 293T cells), and we obtain similar results using COS-7 cells (data not shown). Thus, these data suggest that UPR activation is a graded response rather than an on/off switch.

To confirm the transfection data in Figure 1A, we cultured oligodendrocyte progenitors from *msd* mouse brains and differentiated these cells to induce expression of *Plp1* gene products. Primary transcripts from this gene are alternatively spliced in exon 3 to encode two protein isoforms, PLP1 (contains exon 3a and b) and DM-20 (contains only exon 3a). The smaller DM-20 protein lacks a 35 amino acid hydrophilic peptide (encoded by exon 3b) which is near the center of the protein and is exposed to the cytoplasm (Gow et al., 1997). Remaining exons are present in both mRNAs. Wild-type oligodendrocytes extend processes from the cell body and incorporate DM-20/PLP1 into the plasmalemma (green, Figure 1Da). These processes elaborate membrane sheets that are also DM-20/PLP1 positive. The arrowhead points to the nucleus, which is not labeled by anti-CHOP antibodies. However, nuclei of DM-20/PLP1-positive oligodendrocytes from *msd* mice are robustly CHOP positive, which appears yellow (arrowhead, Figure 1Db), and demonstrates activation of the UPR. In these cells, DM-20/PLP1 staining is largely confined to the perinuclear region, which is a common feature of oligodendrocytes from *Plp1* mutant animals (Williams and Gard, 1997). Debris surrounding the cell body marks the locations of cell processes likely resorbed as accumulating mutant proteins perturbed cell function (arrows).

#### UPR Induction Correlates with *Plp1* Expression in Mutant Mice

In view of our *in vitro* data, we examined expression of the *Chop* gene in *msd* mice with age to determine if induction parallels transcription from the *Plp1* gene. Expression of *Plp1* in spinal cord is low in the perinatal period, and we detect message on Northern blots beginning at P4 in wild-type mice, with a rapid increase thereafter (Figure 2A). Message levels in *msd* mice are detectable by P7 but remain roughly constant beyond this age until death. *Chop* expression in *msd* mice increases

dramatically during the postnatal period, beginning at P7 and corresponding with the age that we detect *Plp1* expression. *Chop* expression is maximal between P16–18 and decreases by P21, near the age of death. This decline may be related to depletion of the oligodendrocyte lineage similar to that reported for the allelic *jimpy* (*jp*) mouse (Knapp et al., 1986), which harbors a splice site mutation causing exon 5 skipping and a frameshift in the remaining coding region (Hudson et al., 1987). Although *Chop* is weakly expressed in controls, the level is constant with age and indicates that induction of this gene is not a feature of normal CNS development. Similar results for *Plp1* and *Chop* are observed in *msd* brains.


In Figure 1C, we observe that mRNA encoding a second bZip transcription factor, ATF3, is induced in 293T cells expressing mutant PLP1. *Atf3* is also strongly induced in spinal cords of *msd* mice, although the time course of induction lags behind that of *Chop* by as much as 6 days (Figure 2A). Furthermore, *Atf3* expression levels decrease earlier than *Chop*, from approximately P15.

Previously, we demonstrated accumulation of mutant DM-20/PLP1 in the perinuclear region of *msd* and *rsh* mouse oligodendrocytes (Gow et al., 1998). We interpret these data in terms of protein misfolding, which suggests that a common molecular mechanism accounts for the phenotypes of these allelic mutants. In support of this notion, we find that both *Chop* and *Atf3* are induced in spinal cords of *rsh* mice compared to littermates at P21 (Figure 2B) as well as in *jp* mice. Together, these data reveal important similarities in pathogenesis for all three mouse mutants despite distinct genetic lesions and disease severities in these animals.

Steady-state mRNA levels of three molecular chaperones in spinal cords of *msd*, *rsh*, and *jp* mice are shown in Figure 2C. In *msd* mice, mRNAs for *BiP*, *Erp59*, and *Erp72* are increased, particularly at P13, when the behavioral phenotype becomes apparent. In similar fashion, *jp* and *rsh* mice exhibit roughly 2-fold increases in the levels of molecular chaperones, which again points to activation of the UPR. Previously, we reported expression of six molecular chaperones induced to varying extents in *msd* and *jp* mice, which implies broad induction of this class of stress-induced genes (Southwood and Gow, 2001). It is likely that relatively modest increases in expression of molecular chaperones in Figure 2C reflect the low abundance of oligodendrocytes in spinal cord (~10% of total cells). Indeed, 5- to 10-fold increases in expression are apparent in optic nerve (Figure 2D), in which oligodendrocytes comprise over 50% of cells.

#### *Chop* Target Genes in the CNS

CHOP is widely believed to play a central role in the UPR, although this role has not been precisely determined. Target genes, or Downstream-Of-CHOP (*Doc*) genes, have been identified using representational difference analysis from tunicamycin-treated fibroblasts (Wang et al., 1998), which prompted us to examine expression of these genes in *Plp1* mutants. Four *Doc* genes induced by CHOP are *Chop* itself (*Doc2*); *Carbonic Anhydrase VI* (*Doc1*); a gene encoding the cytoskeleton binding



**Figure 2.** Temporal Induction of *Chop* and *Atf3* in Spinal Cord from Mutant Mice Correlates with *Plp1* Expression

(A) Northern blots from wild-type (wt) and *msd* mice between P4–P21 express *Plp1*, *Chop*, and *Atf3*. Ethidium bromide-stained 18S rRNA serves as loading controls. (B) Northern blots from wild-type (wt), *jp*, and *rsh* mice at P18 and P21 show that *Chop* and *Atf3* are elevated in the mutants. (C) Northern blots from *msd*, *jp*, and *rsh* mice show induction of molecular chaperones. (D) Northern blots from optic nerve of *msd* mice show induction of UPR effector genes. (E) Northern blots from tunicamycin-treated 3T3 cells (2  $\mu$ g/mL, 4 hr), wild-type, and *msd* mice show that *Doc* genes are not induced by mutant *Plp1* expression. (F) *Doc1* expression cannot be detected by nonquantitative RT-PCR from wild-type or *msd* mice after 35 cycles. Expression of *Docs4* and 6 is detected. (G) Ribonuclease protection assays show that *Doc4* expression is decreased in *msd* mice to 57% of controls. (H) Northern blots show that *Doc4* transcripts are processed differently in wild-type and *msd* mice.

protein, advillin (*Doc6*); and *Doc4*, encoding the evolutionarily conserved teneurin-4 protein. Although expressed by tunicamycin-treated 3T3 cells (Figure 2E), Northern blots demonstrate that these genes are not induced in *msd* spinal cord compared with littermates. Indeed, *Docs1* and 6 are not detected, and *Doc4* mRNA levels actually decrease in the mutants. By nonquantitative RT-PCR, we detect *Doc4* and *Doc6* but not *Doc1* mRNAs, indicating that this latter gene, at least, is not a target of CHOP in the CNS (Figure 2F).

Quantification of *Doc4* levels by ribonuclease protection assays indicate that expression is decreased to 57% of wild-type levels, using  $\beta$ -actin as an internal control (Figure 2G). In addition, Northern blots show that *Doc4* transcripts are differentially processed in *msd* compared to littermates (Figure 2H). Thus, two forms of *Doc4* mRNA, differing in size by 1–2 kilobases, are apparent in wild-type tissue, while only the larger message is present in mutants. The significance of this observation is currently unclear, and we do not know if alternative splicing and/or the use of alternate polyadenylation signals account for the difference. In either case, *Doc4* mRNA processing in response to ER stress was not observed in earlier studies (Wang et al., 1998).

#### Oligodendrocytes Express CHOP and ATF3 In Vivo

Induction of the *Chop* and *Atf3* genes in myelin mutant mice prompted us to identify cells expressing these transcription factors and to determine if the proteins are nuclear localized. Anti-DM-20/PLP1 antibodies strongly label white matter tracts in the cerebellum of P18–21 wild-type mice (Figure 3A). However, CHOP is not detected in any cells in this field (Figure 3B), commensurate with a low level of steady-state mRNA during normal

postnatal development. The DNA stain DAPI reveals glial cell nuclei in the white matter (Figure 3C).

Disease in *msd* mice is accompanied by profuse and widespread oligodendrocyte apoptosis which, by P18, is at an advanced stage in many CNS regions (Gow et al., 1998). Few oligodendrocytes remain in cerebellar white matter, and DM-20/PLP1 staining is principally localized to perinuclear regions of these cells (inset, Figures 3D and 3F). Many oligodendrocytes in the cerebellum express CHOP at high levels, and, most importantly, this protein is nuclear localized (inset, Figures 3E and 3F). Expression and nuclear localization of CHOP in *rsh* oligodendrocytes is similar to that in *msd* mice (inset, Figures 3H and 3I). Thus, together with our previous findings that DM-20/PLP1 trafficking is disrupted in *msd* and *rsh* oligodendrocytes (Gow et al., 1998), Figures 2 and 3 demonstrate similarities in the pathogenesis of these allelic mutants.

Brainstem is another heavily myelinated region of CNS, and DM-20/PLP1 staining in wild-type tissue is shown in Figure 4A. ATF3 is not detected in this field (Figure 4B). In contrast, ATF3-positive oligodendrocytes are observed in *msd* and *rsh* mice (white arrowheads, Figures 4D and 4E, 4G and 4H), although some oligodendrocytes are ATF3 negative (black arrowheads). In addition, PLP1/DM-20 expression is not detected in some ATF3-positive cells (arrows, Figures 4G–4I).

#### Oligodendrocytes and Microglia Express CHOP and ATF3 in Brains of Mutant Mice

Morphometric analyses throughout the brains of three P18 *msd* mice indicate that 100% of CHOP-positive nuclei ( $n = 300$  cells) are from DM-20/PLP1-positive oligodendrocytes (Figure 5). Similarly, counts from two




Figure 3. CHOP Is Localized to Nuclei of DM-20/PLP1<sup>+</sup> Oligodendrocytes in P18 Cerebellum from *msd* and *rsh* Mice

(A) Immunofluorescence labeling in wild-type mice using anti-DM-20/PLP1 antibodies.

(B) CHOP is not detected in this field.

(C) DAPI stain shows locations of nuclei.

(D) DM-20/PLP1 staining in *msd* mice is largely perinuclear (arrowheads).

(E and F) Nuclei are stained with anti-CHOP antibodies (arrowheads).

(G) Anti-DM-20/PLP1 antibodies label *rsh* myelin sheaths in the pons.

(H and I) Oligodendrocyte nuclei are labeled with anti-CHOP antibodies (arrowheads). Inset shows an oligodendrocyte at high magnification with CHOP in the nucleus (arrowhead). Scale bars, 20  $\mu$ m in (B); inset, 3  $\mu$ m.

*rsh* mice reveal that >99% of CHOP-positive oligodendrocytes express DM-20/PLP1 ( $n = 113$ ). However, ATF3-positive, DM-20/PLP1-negative cells account for ~17% ( $n = 109$ ) in *msd* and 31% ( $n = 143$ ) in *rsh* brains. Colocalization analyses (averages from two mice) using cell-specific markers reveal that Mac-3-positive microglia account for  $19\% \pm 3.7\%$  and  $35\% \pm 2.2\%$  of ATF3-positive nuclei in *msd* ( $n = 321$ ) and *rsh* ( $n = 293$ ), respectively. On the other hand, we observe <2% colocalization for ATF3 and S100 $\beta$  (astrocytes) and <1% for ATF3 and Mac-1 (macrophages) or ATF3 and CD3 $\epsilon$  (T cells). Thus, the major cell populations that express ATF3 in CNS of *rsh* and *msd* mice are oligodendrocytes and microglia.

#### The UPR Is Induced Specifically in White Matter of a PMD Patient

To determine the relevance to PMD of our conclusions from previous (Gow et al., 1994b, 1998; Gow and Lazzarini, 1996; Southwood and Gow, 2001) and current analyses, we examined expression of UPR effector genes in autopsy specimens from a patient with multiple sclerosis (MS) and a PMD patient with severe disease caused by a splice site mutation in intron 6 of the *PLP1* gene that causes an in-frame deletion of the 66 base pair exon 6 ( $\Delta$ exon6) in mRNAs from cultured skin fibroblasts

(Hobson et al., 2000). We confirm these data using white matter mRNA by reverse transcriptase-PCR and sequencing of the amplified products; open reading frames from the dominant cDNA species encode putative proteins of 27.8 kDa (PLP1 $\Delta$ exon6) and 24 kDa (DM-20 $\Delta$ exon6). Furthermore, expression of cloned cDNAs in our COS-7 cell paradigm (Gow, 2002; Gow and Lazzarini, 1996) causes accumulation of mutant PLP1 and DM-20 in the ER of transfected cells (Figure 6A).

Oligodendrocytes are widely known to be localized to white matter tracts (WM); however, these cells also reside in gray matter (GM), as reflected in Northern blots of patient tissue probed with human *PLP1* cDNA (Figure 6B). In an MS patient, *CHOP* is expressed at comparable steady-state levels in gray and nonplaque white matter regions. Gray matter is largely comprised of neuronal cell bodies, while white matter is rich with glial cells; thus, different cell types in apparently normal tissue express *CHOP* at low but comparable levels. In contrast, we observe a 5-fold increase in *CHOP* between white and gray matter from the  $\Delta$ exon6 patient, indicating that this gene is selectively induced in the glial cell population. Furthermore, *ATF3*, *BIP*, *ERp59*, and *ERp72* are selectively induced in white matter from this patient. Thus, these data are consistent with our findings in vitro and in animal models demonstrating activation of the




Figure 4. ATF3 Is Localized to Nuclei of DM-20/PLP1<sup>+</sup> Oligodendrocytes in Brainstem from *msd* and *rsh*

(A) Immunofluorescence labeling of white matter from wild-type mice using anti-DM-20/PLP1 antibodies.

(B) ATF3 is not detected in this field. Scale bar, 20  $\mu$ m.

(C) DAPI stain shows locations of nuclei.

(D) DM-20/PLP1 staining in *msd* mice is largely perinuclear (arrowheads).

(E and F) Nuclei in some oligodendrocytes are stained with anti-ATF3 antibodies (white arrowheads); others are unstained (black arrowheads).

(G) Anti-DM-20/PLP1 antibodies label oligodendrocytes (arrowheads) and myelin sheaths in *rsh* mice.

(H and I) Some cells are labeled with anti-ATF3 antibodies (white arrowheads), while others are ATF3<sup>-</sup> (black arrowheads). Arrows show ATF3<sup>+</sup>, DM-20/PLP1<sup>+</sup> cells.

UPR in response to coding region mutations in the *PLP1* gene. Comparable *CHOP* expression in gray matter of the MS and  $\Delta$ exon6 patients suggests that metabolic stress in neurons is not a significant pathogenic feature




Figure 5. Oligodendrocytes and Microglia Comprise the CHOP<sup>+</sup> and ATF3<sup>+</sup> Cell Populations in Brains of *msd* and *rsh* Mice

Essentially all CHOP<sup>+</sup> cells in the CNS of *msd* and *rsh* mice are oligodendrocytes. Oligodendrocytes and microglia are the major cell populations comprising ATF3<sup>+</sup> cells.

of PMD. Interestingly, *BIP* expression in gray matter from the MS patient is elevated above white matter; however, its significance is currently unknown.

#### MBP-Positive Oligodendrocytes in a PMD Patient Localize CHOP to the Nucleus

To determine the identity of *CHOP*-expressing cells in white matter from the  $\Delta$ exon6 patient, we labeled paraffin sections from neocortex with antibodies against myelin basic protein (MBP) and *CHOP* (Figure 6C). MBP strongly labels myelin membrane around axons (double arrow, Figure 6Ca) as well as the plasma membrane of an oligodendrocyte cell body (arrow). This cell also expresses *CHOP* in the nucleus (Figure 6Cb), which is evident from its colocalization with the nuclear stain DAPI (Figure 6Cc). Three additional cells are weakly MBP positive and express *CHOP* in the cytoplasm (arrowheads, inset). Presumably, these cells are at the initial stage of synthesizing myelin proteins such as MBP and DM-20/PLP1 and have induced the UPR, although it appears that nuclear translocation of *CHOP* has not yet occurred. We are unable to detect DM-20/PLP1 or ATF3 in brain sections from this patient using several antibodies.






Figure 6. *CHOP* and *ATF3* Are Induced in White Matter from a PMD Patient Harboring the  $\Delta$ exon6 Mutation

(A) Immunofluorescence labeling of mutant PLP1 (Aa) and DM-20 (Ab) encoded by cDNAs from a  $\Delta$ exon6 PMD patient show protein accumulating in the ER of transfected COS-7 cells. Scale bar, 5  $\mu$ m.

(B) Northern blot of white matter (WM) and gray matter (GM) from a multiple sclerosis patient (MS) and a  $\Delta$ exon6 PMD patient. 18S serves as loading controls.

(C) An oligodendrocyte (arrow) labeled with anti-MBP antibodies (Ca) expresses CHOP (Cb) in the nucleus (Cc). Three additional oligodendrocytes (arrowheads and inset) express CHOP in the cytoplasm. Scale bar, 5  $\mu$ m.

### CHOP Modulates Disease Severity in *rsh* Mice

The data presented in Figures 1–5 suggest a role for CHOP in pathogenesis associated with coding region mutations in the *PLP1* gene. Early in vivo experiments demonstrate that epithelial cells in the kidneys of mice undergo CHOP-dependent apoptosis with a predictable time course after acute tunicamycin toxicity (Wang et al., 1998).

To determine if CHOP modulates pathogenesis associated with *Plp1* mutations, we crossed *Chop* null mice (Zinszner et al., 1998) with *rsh* mice to generate *Chop* null/*rsh* double mutants. A Kaplan-Meier analysis of these mice is shown in Figure 7, where the ordinate indicates the number of mice for each genotype (see

Experimental Procedures for husbandry details). Wild-type and *Chop* null mice, which have no known phenotype, live beyond 20 weeks of age. Similarly, *rsh* mice exhibit normal longevity, as shown previously (Schneider et al., 1992). In dramatic contrast, disease in *Chop* null/*rsh* mice is substantially more severe than that conferred by the *rsh* mutation alone, and double mutants exhibit frequent seizures induced by sudden noise, handling, or startle responses. These mice die as early as 5 weeks of age and have an average life span of less than 10 weeks. Despite apparent longevity, *rsh* mice that harbor a single functional *Chop* gene exhibit occasional seizures, consistent with an intermediate phenotype stemming from haplo-insufficiency at the *Chop* locus.




Figure 7. Kaplan-Meier Analysis and Oligodendrocyte Apoptosis in *Chop* Null/*rsh* Mice

(A) Survival over 20 weeks in sib cohorts of wild-type, *rsh*, *Chop* null, *Chop* null/*rsh*, and *Chop*-het/*rsh* mice. The ordinate indicates the number of mice in each cohort.

(B) Levels of apoptosis are 5-fold higher in cervical spinal cord from P16 *msd* mice compared to controls.

(C) Electron micrographs show (Ca) a morphologically normal oligodendrocyte from a *Chop* null mouse surrounded by myelinated fibers and (Cb) an apoptotic oligodendrocyte from a *Chop* null/*rsh* mouse with condensed chromatin (arrowhead) surrounded by large unmyelinated axons (asterisks). Scale bar, 1  $\mu$ m.

Together, these data provide direct evidence for a pivotal role of CHOP in pathogenesis and demonstrate that the activity of this transcription factor serves to ameliorate the toxic effects of mutant DM-20/PLP1 in oligodendrocytes.

#### Oligodendrocyte Apoptosis in *Chop* Null/*rsh* Mice

In a hunt for cellular mechanisms that account for high mortality in *Chop* null/*rsh* mice, we examined levels of apoptosis in CNS, which are elevated for *Plp1* mutants with severe forms of disease (Schneider et al., 1992). At early postnatal ages, the number of TUNEL-positive cells in cervical spinal cord from *Chop* null/*rsh* mice is elevated ~5-fold over age-matched controls (Figure 7B), and by 10 weeks, apoptotic oligodendrocytes are widespread in optic nerve and spinal cord from double mutants. A morphologically normal oligodendrocyte surrounded by myelinated axons (arrows) in optic nerve from a *Chop* null mouse is shown in Figure 7Ca. On the other hand, many oligodendrocytes in *Chop* null/*rsh* mice have abnormally shaped nuclei and exhibit regions of condensed chromatin around the nuclear membrane (arrowhead, Figure 7Cb). Moreover, oligodendrocyte loss and dysfunction is evident from the large number of unmyelinated axons in these mutants (asterisks). Thus, these data demonstrate that CHOP plays a critical role in protecting oligodendrocytes from the detrimental consequences of unfolded proteins in the ER and are consistent with the correlation between oligodendrocyte death and shortened life span of *PLP1* mutants with severe forms of disease, such as *msd* and *jp* mice.

#### Discussion

Although several features of the UPR are well-characterized, a rapid expansion in our understanding of this signaling cascade has occurred only since identification of the upstream initiating elements of the pathway—such as ATF6, Ire1, and PERK—as well as molecular chaperones and transcription factors, which effect changes in gene expression upon UPR activation. In this study, we examine expression of two effector proteins, CHOP and ATF3, in PMD brain as well as animal models, and find them to be nuclear localized in oligodendrocytes expressing mutant *PLP1* gene products. Furthermore, we show induction of several molecular chaperones. Finally, we demonstrate direct involvement of CHOP in the pathogenesis of PMD and reveal novel and important features of the UPR in oligodendrocytes, as indicated below.

First, CHOP does not serve identical functions in oligodendrocytes to those demonstrated in fibroblasts and kidney proximal tubule epithelial cells. For example, DNA condensation and fragmentation in kidney cells from tunicamycin-treated *Chop* null mice are not prominent features of pathology, in stark contrast to control animals. Thus, CHOP is required for apoptosis of these cells (Zinszner et al., 1998). However, oligodendrocytes in optic nerve and spinal cord from *Chop* null/*rsh* mice undergo apoptosis with greater frequency than in controls (Figure 7). These data reveal a major divergence in importance of CHOP as a central mediator of cell death for different cell types which, conceivably, could

be related to the cell type-specific target genes of this transcription factor. Nevertheless, available data convincingly indicates that CHOP is a key regulatory component of the UPR in kidney cells and oligodendrocytes.

Additional diversity in cell type-specific functions of *Chop* is revealed in a recent examination of diabetic Akita mice. This mouse harbors a C96Y missense mutation in the *Insulin2* gene, and a single mutant allele leads to hyperglycemia in the first month of life (Oyadomari et al., 2002). Interestingly, hyperglycemia develops at a slightly later age in the absence of the *Chop* gene (i.e., *Ins2<sup>WT/C96Y</sup>*, *Chop* null mice), and pancreatic  $\beta$  cells undergo cell death with reduced frequency. On the other hand, apoptosis of  $\beta$  cells in Akita mice with two mutant *Insulin2* alleles is equally widespread in the presence or absence of CHOP. These data indicate that *Chop* is not required for pancreatic  $\beta$  cell death in the context of the UPR, similar to oligodendrocytes. Nonetheless, CHOP in  $\beta$  cells exhibits weak proapoptotic properties which contrast with its strong prosurvival role in oligodendrocytes from *rsh* mice.

In support of cell type-specific functions for CHOP, we find that target genes in oligodendrocytes overlap with but are distinct from those in other cell types. Thus, *Chop* induction in *msd* mice does not induce expression of *Docs 1*, *4*, and *6*, in contrast to mouse embryonic fibroblasts treated with tunicamycin (Wang et al., 1998). The molecular basis underlying this cell-specific target gene selection is currently unknown, but a likely possibility is the partnering of CHOP with oligodendrocyte-specific bZip transcription factors. Nevertheless, we cannot exclude the prospect that target gene selection arises from unique aspects of UPR induction, such as acute tunicamycin exposure versus persistent *PLP1* gene expression.

A second feature of the UPR to emerge from this study is that *CHOP* expression (and *ATF3*) is not a prelude to programmed cell death under all conditions, an important divergence that dramatically alters the life span of and disease severity in *Plp1* mutant mice. In *msd* and *jp* mice, oligodendrocyte apoptosis is widespread in the CNS (Gow et al., 1998) and depletes this cell lineage shortly before the animals die (Knapp et al., 1986). On the other hand, oligodendrocyte populations in white matter tracts of *rsh* mice are slightly expanded compared to controls (Fanarraga et al., 1992), which may reflect compensation to overcome diminished myelin synthesis and/or reduced numbers of axons ensheathed per cell. These data suggest common features of pathogenesis in *rsh*, *msd*, and *jp* mice, despite substantial differences in life span. Thus, activation of the UPR per se does not govern oligodendrocyte survival or disease severity, which must be regulated by additional factors (Gow and Lazzarini, 1996).

Third, UPR activation appears to be limited to genetic forms of PMD causing coding region mutations in *PLP1*. For example, immunocytochemical analyses of brain and spinal cord from *4e-Plp* mice, which overexpress a wild-type *Plp1* transgene in oligodendrocytes (Kagawa et al., 1994), indicate that the UPR is not induced; indeed, we are unable to detect expression of either CHOP or ATF3 in oligodendrocytes from these mutants. Furthermore, expression of these transcription factors is not induced in white matter from a PMD patient harboring






Figure 8. Possible Models to Account for the Correlation between Disease Severity in PMD and DM-20/PLP1 Trafficking Defects

(A) UPR portrayed as a graded response that is proportional to the level of misfolded protein in the ER; the higher the level, the stronger the UPR. (Aa) Mutations causing ER accumulation of both PLP1 and DM-20 induce a strong UPR. (Ab) Mutations causing accumulation of PLP1 but not DM-20 induce a weak response.

(B) UPR portrayed as an off/on switch upon misfolded protein accumulation. (Ba) PLP1 and DM-20 accumulation induces the UPR. DM-20 is toxic and disrupts cell survival pathways (?). (Bb) Accumulation of only PLP1 in the ER induces the UPR but does not affect cell survival pathways.

a *PLP1* duplication (data not shown). Morphological evidence also distinguishes disease caused by coding region mutations versus overexpression. In transgenic mice overexpressing *Plp1*, the major ultrastructural defect observed in oligodendrocytes is distention of Golgi cisternae (Kagawa et al., 1994; Readhead et al., 1994), while *Plp1* coding region mutations distend the ER (Duncan, 1990). In accord with these ultrastructural changes, we anticipate a UPR associated with the latter but not the former genetic form of PMD. However, perhaps the strongest evidence of a distinct pathogenic mechanism for *Plp1* overexpression is revealed by a recent study showing inappropriate targeting to lysosomes of cholesterol and lipid raft components, which are normally sorted to the Golgi (Simons et al., 2002).

Consistent with variable disease severity observed for different *PLP1* coding region mutations, we speculate that upstream elements of the UPR confer a graded response to metabolic stress: the greater the accumulation, the more intense the UPR and the higher the likelihood of apoptosis. Several studies support this model. For example, we previously described a cellular mechanism that accounts for disease severity in PMD on the basis of the amount of *PLP1* gene products accumulating in the ER (Gow and Lazzarini, 1996). The interpretation from these data and additional mutations (A.G., unpublished data) is illustrated in Figure 8A. Thus, eight missense mutations causing ER accumulation of both DM-20 and PLP1 (including *msd*) give rise to severe disease (Figure 8Aa). In contrast, nine mutations that disrupt trafficking to the cell surface of PLP1 but not DM-20 (including *rsh*) cause mild disease (Figure 8Ab). Furthermore, wild-type or mutant forms of DM-20 that traverse the secretory pathway can transport mutant PLP1 out of the ER, which, presumably, reduces levels

of misfolded protein in this organelle (Gow and Lazzarini, 1996). Finally, we show in Figure 1C that, on a per cell basis, the glycoprotein synthesis inhibitor tunicamycin induces *Chop* expression far more effectively than does *PLP1<sup>msd</sup>*, although *Atf3* and *BiP* are induced with similar efficiencies.

Other studies provide evidence of variable disease severity that is consistent with a graded UPR. When expressed in oligodendrocytes of transgenic mice, the H-2K<sup>b</sup> MHC protein accumulates in the ER and causes hypomyelination above a threshold of transgene expression (Baerwald et al., 2000; Power et al., 1996; Turnley et al., 1991). This threshold can be breached in hemizygotes by high-level transgene expression or by mating two asymptomatic lines. Moreover, expression significantly above this threshold also decreases life span to 3 weeks and causes widespread, nonimmune-mediated oligodendrocyte apoptosis. In analogous experiments, high-level expression of  $\beta$  cells and diabetes, again by a nonimmune mechanism (Allison et al., 1988). Presumably, these cells are particularly sensitive to overwhelming the ER or disrupting the UPR, because knockout mice that lack the gene encoding the UPR initiator receptor kinase PERK also exhibit high levels of  $\beta$  cell death and diabetes (Harding et al., 2001).

Despite considerable precedence for graded UPR signaling, we cannot formally exclude the possibility that severe forms of PMD result specifically from disrupting DM-20 trafficking (Figure 8B). For example, *rsh* and *msd* mutations may activate the UPR in oligodendrocytes to similar extents; however, accumulation of DM-20 in the ER of *msd* oligodendrocytes may activate additional pathways ("?" in Figure 8Ba) that block survival mechanisms normally regulated by the UPR. Alternatively, accumulation of mutant DM-20 in the ER but not mutant PLP1 may be particularly toxic to cells.

Recent appreciation of the UPR has led to speculation that disrupting or overwhelming this signaling cascade might play a role in pathogenesis for a number of degenerative diseases (Aridor and Balch, 1999). Herein, we show that *PLP1* mutations induce the UPR and that disruption of this pathway dramatically increases disease severity. Thus, PMD is the first example of a degenerative disease where the UPR modulates pathogenesis. In the search for additional UPR-linked diseases, it is important to develop criteria that exclude diseases arising from other pathogenic mechanisms. In this vein, null alleles should confer a phenotype that is significantly more mild than or clinically distinct from at least some coding region mutations. This criterion rules out mutations that simply abolish protein function. This is the case for *PLP1* and for  $\alpha_1$ -*ANTITRYPSIN*, where null mutations cause emphysema and missense mutations accumulating in the ER cause hepatitis (Dycaico et al., 1988).

A second distinguishing feature of UPR-linked diseases is dominant or semidominant inheritance, at least at the level of individual cells. PMD is technically a recessive disease, because *PLP1* is located on the X chromosome, and carrier females rarely develop symptoms. However, mutant *PLP1* gene products act dominantly because the *jp* phenotype cannot be rescued with a wild-type *Plp1* transgene (Schneider et al., 1995). Addi-

tional features for this class of diseases require in vivo and in vitro expression studies to determine if mutant genes encode secretory pathway proteins that accumulate in the ER. Thus, protein aggregation is a prominent feature of trinucleotide repeat diseases such as Huntington disease, but this aggregation often occurs in the nucleus and would not be expected to induce the UPR.

## Experimental Procedures

### Primary Oligodendrocyte Cultures and Transfected Cells

Brains from P2 male pups were dissociated by trituration through 18G, 21G, and 25G needles in HEPES-buffered MEM (Life Technologies), pelleted, and plated onto poly-ornithine-coated T25 flasks in high-glucose DMEM containing 15% FCS (Hyclone), 1 mM pyruvate, 1.5 g/l glucose, and Pen-Strep (Life Technologies). Cultures were grown at 37°C for 2 weeks, with media changes every 2–3 days. Oligodendrocyte progenitors were recovered by light trypsin digestion (ATV trypsin, Irvine Scientific, CA) and differentiated at low density on coated plastic 35 mm dishes (Nunc) in high-glucose DMEM containing 2% FCS, pyruvate, glucose, and antibiotics. cDNAs encoding wild-type and mutant DM-20/PLP1 were expressed for 1–2 days using pCMV5 (Lorenz et al., 1990) in FUGENE-6-transfected COS-7 or 293T cells (Gow, 2002).

### Autopsy Specimens from PMD and MS Patients

Gray and white matter regions were dissected from the cortex of the *Δxon6* PMD patient at autopsy (9 hr postmortem) and either frozen on dry ice or immersion fixed in 10% formalin for several weeks at 4°C before paraffin processing. Brain hemispheres from the MS patient (13.5 hr postmortem) were frozen on dry ice at autopsy and stored at –80°C.

### Northern Blotting, RT-PCR, and Ribonuclease-Protection Assays

Total RNA was purified from homogenates of frozen tissue by CsCl centrifugation using a Beckman SW50.1 rotor (Chirgwin et al., 1979). Several spinal cords from young mice were pooled, and human tissue samples weighed 0.5–1 gm. Ten microgram RNA samples were run on 1%–1.5% formaldehyde-agarose gels, blotted, probed (Gow et al., 1999), and washed at 58°C (*Chop*, *Atf3* probes) or 55°C (other probes) in 0.2 × SSPE and 0.1% SDS. Exposures of autoradiograms were adjusted to yield nonsaturated hybridization signals with similar intensities for each sample. The signals were digitized, quantified by integration of the scanned peaks, and adjusted for exposure time. Oligo-dT priming from 10 μg of total mRNA was performed as recommended (Invitrogen), and 20% of each reaction was used for 35 cycle-PCR with primers defined previously (Wang et al., 1998). Product identities were confirmed by size and restriction enzyme mapping. Probes for ribonuclease protection assays were <sup>32</sup>P-UTP labeled using T7 polymerase (Stratagene). Standard hybridization conditions (Ambion) were used prior to RNase A treatment and nondenaturing PAGE in 5% gels. Probes: *Doc4*, 230 bp of 3' coding region; β-actin, 72 bp of 5' coding region.

### Immunocytochemistry and TUNEL Labeling

Mice were perfused intracardially for 30 min with 4% paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.2). Brains were dissected, cut along the midline, and embedded in O.C.T. at –80°C. Ten μm parasagittal sections were immunolabeled (Gow et al., 1998). Seven μm sections of cortex from the *Δxon6* PMD patient were de-waxed, hydrated, treated with 1 × TUF fluid as recommended (Zymed, CA), and immunolabeled. Antibodies used were rat anti-DM-20/PLP1 (1:5, hybridoma AA3, Yamamura et al., 1991); mouse anti-MBP (1:1000, mix of hybridomas SMI94 and SMI99, Sternberger Inc.); rabbit anti-CHOP (1:300, a kind gift from Dr. David Ron, Skirball Institute, New York); rabbit anti-ATF3 (1:300, C-19, Santa Cruz); 2 × mouse anti-S100β antibodies (1:100, SH-B1, Sigma); rat anti-Mac-1 (1:50, Pharmingen); rat anti-Mac-3 (1:50, Pharmingen); hamster anti-CD3ε (1:50, Pharmingen). Pharmingen antibodies were used to label 6 μm fresh frozen brain sections fixed/permeabilized with methanol for 10 min, then subsequently fixed

with 2% paraformaldehyde and labeled with anti-ATF3 antibodies. Secondary antibodies were from Vector Labs (Burlingame, CA) and Southern Biotech (Birmingham, AL). TUNEL labeling was carried out on 10 μm transverse spinal cord cryostat sections (Gow et al., 1998).

### Kaplan-Meier Analysis

This analysis was carried out in three concurrent phases. First, *Chop* null male mice (Zinszner et al., 1998) with a wild-type *Plp1* gene (i.e., *Chop*<sup>–/–</sup>, *X/Y*) on a mixed B6C3H F<sub>1</sub> (Taconic Farms, NY) / 129 Sv/SW background were mated to *rsh* carrier female mice (i.e., *Chop*<sup>+/+</sup>, *rsh/X*) on a B6C3H F<sub>1</sub> (Taconic Farms) background (gift from Dr. S. Billings-Gagliardi, University of Massachusetts, MA), then to the *Chop*<sup>+/–</sup>, *rsh/X* progeny to generate *Chop*<sup>–/–</sup>, *rsh/X* carrier females. These double mutants were sib mated to *Chop*<sup>–/–</sup>, *X/Y* mice, and male progeny with genotypes of either *Chop*<sup>–/–</sup>, *X/Y* (*Chop* null) or *Chop*<sup>–/–</sup>, *rsh/Y* (*Chop* null/*rsh*) were generated with equal frequency from ten litters for analysis. Second, *Chop*<sup>–/–</sup>, *rsh/X* carrier females were mated with wild-type hybrid mice to generate *Chop*<sup>+/–</sup>, *rsh/Y* mice from one litter for analysis (*Chop*-het/*rsh*). Third, *Chop*<sup>+/–</sup>, *rsh/X* females were sib mated with *Chop*<sup>+/–</sup>, *X/Y* males to recover the *rsh* allele on a *Chop*<sup>+/+</sup> background. Female *Chop*<sup>+/+</sup>, *rsh/X* carriers were sib mated with *Chop*<sup>+/+</sup>, *X/Y* males to generate male wild-type and *rsh* sib cohorts from six litters for analysis. Cohorts of *Chop* null and *Chop* null/*rsh* or Wild-Type and *rsh* mice comprise multiple sets of sibs housed in open cages. A nonparametric ANOVA (Kruskal-Wallis test) of *Chop* null/*rsh* mice revealed no statistical differences in average life span between individual litters (*p* = 0.36).

### Acknowledgments

We dedicate this research to the memory of Dr. M.E. Hodes at the University of Minneapolis for his eminent contributions to the molecular characterization of *PLP1* gene mutations for so many families living with Pelizaeus-Merzbacher disease. We acknowledge excellent technical support from Jingsong Li, Milena Pariali, Brunella Bertucci, Anita Chalasani, and Cunli Xiang; patient referrals by Drs. Grace Hobson (DuPont, Delaware) and Franca Cambi (Thomas Jefferson University, Philadelphia); as well as critical discussions and reagents from Drs. David Ron (Skirball Institute of Biomolecular Medicine, New York), John Kamholz, and Gerard Tromp (Wayne State University School of Medicine). This work was supported by grants to A.G. from the National Multiple Sclerosis Society (RG2891 B-2), National Institutes of Health (RO1 NS43783), and by grants to A.G. and J.G. from the Children's Research Center of Michigan.

Received: May 21, 2002

Revised: September 10, 2002

### References

- Allison, J., Campbell, I.L., Morahan, G., Mandel, T.E., Harrison, L.C., and Miller, J.F.A.P. (1988). Diabetes in transgenic mice resulting from over-expression of class I histocompatibility molecules in pancreatic β cells. *Nature* 333, 529–533.
- Aridor, M., and Balch, W.E. (1999). Integration of endoplasmic reticulum signaling in health and disease. *Nat. Med.* 5, 745–751.
- Baerwald, K.D., Corbin, J.G., and Popko, B. (2000). Major histocompatibility complex heavy chain accumulation in the endoplasmic reticulum of oligodendrocytes results in myelin abnormalities. *J. Neurosci. Res.* 59, 160–169.
- Chirgwin, J., Przybyla, A., MacDonald, R., and Rutter, W. (1979). Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. *Biochemistry* 18, 5294–5299.
- Duncan, I.D. (1990). Dissection of the phenotype and genotype of the X-linked myelin mutants. In *Myelination and Dysmyelination*, I.D. Duncan, R.P. Skoff, and D.R. Colman, eds. (New York: New York Academy of Sciences), pp. 110–121.
- Dycaico, M.J., Grant, S.G., Felts, K., Nichols, W.S., Geller, S.A., Hager, J.H., Pollard, A.J., Kohler, S.W., Short, H.P., Jirik, F.R., et al. (1988). Neonatal hepatitis induced by alpha 1-antitrypsin: a transgenic mouse model. *Science* 242, 1409–1412.
- Fanarraga, M.L., Griffiths, I.R., McCulloch, M.C., Barrie, J.A., Ken-

- nedy, P.G., and Brophy, P.J. (1992). Rumpshaker: an X-linked mutation causing hypomyelination: developmental differences in myelination and glial cells between the optic nerve and spinal cord. *Glia* 5, 161–170.
- Garbern, J., Cambi, F., Shy, M., and Kamholz, J. (1999). The molecular pathogenesis of Pelizaeus-Merzbacher disease. *Arch. Neurol.* 56, 1210–1214.
- Gencic, S., and Hudson, L.D. (1990). Conservative amino acid substitution in the myelin proteolipid protein of jimpy<sup>msd</sup> mice. *J. Neurosci.* 10, 117–124.
- Gow, A. (2002). The COS-7 cell in vitro paradigm to study myelin proteolipid protein gene mutations. In *Neurogenetics: Methods And Protocols*, N. Potter, ed. (Totowa, NJ: Humana Press), pp. 263–275.
- Gow, A., and Lazzarini, R.A. (1996). A cellular mechanism governing the severity of Pelizaeus-Merzbacher disease. *Nat. Genet.* 13, 422–428.
- Gow, A., Friedrich, V.L., and Lazzarini, R.A. (1994a). Intracellular transport and sorting of the oligodendrocyte transmembrane proteolipid protein. *J. Neurosci. Res.* 37, 563–573.
- Gow, A., Friedrich, V.L., and Lazzarini, R.A. (1994b). Many naturally occurring mutations of myelin proteolipid protein impair its intracellular transport. *J. Neurosci. Res.* 37, 574–583.
- Gow, A., Gragerov, A., Gard, A., Colman, D.R., and Lazzarini, R.A. (1997). Conservation of topology, but not conformation, of the proteolipid proteins of the myelin sheath. *J. Neurosci.* 17, 181–189.
- Gow, A., Southwood, C.M., and Lazzarini, R.A. (1998). Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of Pelizaeus-Merzbacher disease. *J. Cell Biol.* 140, 925–934.
- Gow, A., Southwood, C.M., Li, J.S., Pariali, M., Riordan, G.P., Brodie, S.E., Danias, J., Bronstein, J.M., Kachar, B., and Lazzarini, R.A. (1999). CNS myelin and sertoli cell tight junction strands are absent in *Osp/Claudin 11*-null mice. *Cell* 99, 649–659.
- Griffiths, I.R., Scott, I., McCulloch, M.C., Barrie, J.A., McPhilemy, K., and Cattaneach, B.M. (1990). Rumpshaker mouse: a new X-linked mutation affecting myelination: evidence for a defect in PLP expression. *J. Neurocytol.* 19, 273–283.
- Griffiths, I., Klugmann, M., Anderson, T., Yool, D., Thomson, C., Schwab, M.H., Schneider, A., Zimmermann, F., McCulloch, M., Nado, N., and Nave, K.-A. (1998). Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. *Science* 280, 1610–1613.
- Harding, H.P., Novoa, I., Zhang, Y., Zeng, H., Wek, R., Schapira, M., and Ron, D. (2000). Regulated translation initiation controls stress-induced gene expression in mammalian cells. *Mol. Cell* 6, 1099–1108.
- Harding, H.P., Zeng, H., Zhang, Y., Jungries, R., Chung, P., Plesken, H., Sabatini, D.D., and Ron, D. (2001). Diabetes mellitus and exocrine pancreatic dysfunction in *perk*<sup>-/-</sup> mice reveals a role for translational control in secretory cell survival. *Mol. Cell* 7, 1153–1163.
- Hobson, G.M., Davis, A.P., Stowell, N.C., Kolodny, E.H., Sistermans, E.A., de Co, I.F., Funanage, V.L., and Marks, H.G. (2000). Mutations in noncoding regions of the proteolipid protein gene in Pelizaeus-Merzbacher disease. *Neurology* 55, 1089–1096.
- Hudson, H.D., Berndt, J.A., Puckett, C., Kozak, C.A., and Lazzarini, R.A. (1987). Aberrant splicing of proteolipid protein mRNA in the dysmyelinating jimpy mutant mouse. *Proc. Natl. Acad. Sci. USA* 84, 1454–1458.
- Ikenaka, K., and Kagawa, T. (1995). Transgenic systems in studying myelin gene expression. *Dev. Neurosci.* 17, 127–136.
- Kagawa, T., Ikenaka, K., Inoue, Y., Kuriyama, S., Tsujii, T., Nakao, J., Nakajima, K., Aruga, J., Okano, H., and Mikoshiba, K. (1994). Glial cell degeneration and hypomyelination caused by overexpression of myelin proteolipid protein gene. *Neuron* 13, 427–442.
- Katayama, T., Imaizumi, K., Sato, N., Miyoshi, K., Kudo, T., Hitomi, J., Morihara, T., Yoneda, T., Gomi, F., Mori, Y., et al. (1999). Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. *Nat. Cell Biol.* 1, 479–485.
- Klugmann, M., Schwab, M.H., Puhlhofer, A., Schneider, A., Zimmermann, F., Griffiths, I.R., and Nave, K.-A. (1997). Assembly of CNS myelin in the absence of proteolipid protein. *Neuron* 18, 59–70.
- Knapp, P., Skoff, R., and Redstone, D. (1986). Oligodendroglial cell death in jimpy mice: an explanation for the myelin deficit. *J. Neurosci.* 6, 2813–2822.
- Kobayashi, H., Hoffman, E.P., and Marks, H.G. (1994). The *rumpshaker* mutation in spastic paraplegia. *Nat. Genet.* 7, 351–352.
- Lorence, M.C., Murry, B.A., Trant, J.M., and Mason, J.I. (1990). Human 3 $\beta$ -hydroxysteroid dehydrogenase/ $\Delta^5$ - $\Delta^4$  isomerase from placenta: expression in nonsteroidogenic cells of a protein that catalyzes the dehydrogenation/isomerization of C21 and C19 steroids. *Endocrinology* 126, 2493–2498.
- Ma, Y., and Hendershot, L.M. (2001). The unfolding tale of the unfolded protein response. *Cell* 107, 827–830.
- Ma, Y., Brewer, J.W., Diehl, J.A., and Hendershot, L.M. (2002). Two distinct stress signaling pathways converge upon the CHOP promoter during the mammalian unfolded protein response. *J. Mol. Biol.* 318, 1351–1365.
- Niwa, M., Sidrauski, C., Kaufman, R.J., and Walter, P. (1999). A role for presenilin-1 in nuclear accumulation of Ire1 fragments and induction of the mammalian unfolded protein response. *Cell* 99, 691–702.
- Okada, T., Yoshida, H., Akazawa, R., Negishi, M., and Mori, K. (2002). Distinct roles of ATF6 and PERK in transcription during the mammalian unfolded protein response. *Biochem. J.* 16.
- Oyadomari, S., Koizumi, A., Takeda, K., Gotoh, T., Akira, S., Araki, E., and Mori, M. (2002). Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes. *J. Clin. Invest.* 109, 525–532.
- Power, C., Kong, P., and Trapp, B. (1996). Major histocompatibility class I expression in oligodendrocytes induces hypomyelination in transgenic mice. *J. Neurosci. Res.* 44, 165–173.
- Readhead, C., Schneider, A., Griffiths, I.R., and Nave, K.-A. (1994). Premature arrest of myelin formation in transgenic mice with increased proteolipid protein gene dosage. *Neuron* 12, 583–595.
- Rosenbluth, J., Stoffel, W., and Schiff, R. (1996). Myelin structure in proteolipid protein (PLP)-null mouse spinal cord. *J. Comp. Neurol.* 371, 336–344.
- Sato, N., Urano, F., Yoon Leem, J., Kim, S.H., Li, M., Donoviel, D., Bernstein, A., Lee, A.S., Ron, D., Veselits, M.L., et al. (2000). Upregulation of BiP and CHOP by the unfolded-protein response is independent of presenilin expression. *Nat. Cell Biol.* 2, 863–870.
- Schneider, A., Montague, P., Griffiths, I., Fanarraga, M., Kennedy, P., Brophy, P., and Nave, K.-A. (1992). Uncoupling of hypomyelination and glial cell death by a mutation in the proteolipid protein gene. *Nature* 358, 758–761.
- Schneider, A., Griffiths, I., Readhead, C., and Nave, K.-A. (1995). Dominant-negative action of the jimpy mutation in mice complemented with an autosomal transgene for myelin proteolipid protein. *Proc. Natl. Acad. Sci. USA* 92, 4447–4451.
- Simons, M., Kramer, E.M., Macchi, P., Rathke-Hartlieb, S., Trotter, J., Nave, K.A., and Schulz, J.B. (2002). Overexpression of the myelin proteolipid protein leads to accumulation of cholesterol and proteolipid protein in endosomes/lysosomes: implications for Pelizaeus-Merzbacher disease. *J. Cell Biol.* 157, 327–336.
- Southwood, C.M., and Gow, A. (2001). Molecular mechanisms of disease stemming from mutations in the proteolipid protein gene. *Microsc. Res. Tech.* 52, 700–708.
- Stecca, B., Southwood, C.M., Gragerov, A., Kelley, K.A., Friedrich, V.L.J., and Gow, A. (2000). The evolution of lipophilin genes from invertebrates to tetrapods: DM-20 cannot replace PLP in CNS myelin. *J. Neurosci.* 20, 4002–4010.
- Travers, K.J., Patil, C.K., Wodicka, L., Lockhart, D.J., Weissman, J.S., and Walter, P. (2000). Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation. *Cell* 101, 249–258.
- Turnley, A.M., Morahan, G., Okano, H., Bernard, O., Mikoshiba, K., Allison, J., Bartlett, P.F., and Miller, J.A.F.P. (1991). Dysmyelination

in transgenic mice resulting from expression of class I histocompatibility molecules in oligodendrocytes. *Nature* 353, 566–569.

Wang, X.-Z., Kuroda, M., Sok, J., Batchvarova, N., Kimmel, R., Chung, P., Zinszner, H., and Ron, D. (1998). Identification of novel stress-induced genes downstream of *chop*. *EMBO J.* 17, 3619–3630.

Williams, W.C., 2nd, and Gard, A.L. (1997). In vitro death of jimpy oligodendrocytes: correlation with onset of DM-20/PLP expression and resistance to oligodendroglial trophic factors. *J. Neurosci. Res.* 50, 177–189.

Yamamoto, T., Nanba, E., Zhang, H., Sasaki, M., Komaki, H., and Takeshita, K. (1998). Jimpy(msd) mouse mutation and congenital Pelizaeus-Merzbacher disease. *Am. J. Med. Genet.* 75, 439–440.

Yamamura, T., Konola, J.T., Wekerle, H., and Lees, M.B. (1991). Monoclonal antibodies against myelin proteolipid protein: identification and characterization of two major determinants. *J. Neurochem.* 57, 1671–1680.

Zinszner, H., Kuroda, M., Wang, X., Batchvarova, N., Lightfoot, R.T., Remotti, H., Stevens, J.L., and Ron, D. (1998). CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. *Genes Dev.* 12, 982–995.